Theriva Biologics Announces 1-For-30 Reverse Stock Split, Effective December 1
Benzinga Newsdesk 6 hours ago
NewsStock Split
Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today a reverse stock split of its
Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today a reverse stock split of its authorized and issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every thirty (30) shares of common stock, effective as of 11:59 p.m. (Eastern Time) on December 1, 2026 (the "Effective Date").
The Company’s common stock will begin trading on a split-adjusted basis when the market opens on December 2, 2026. The reverse stock split was authorized by the Company’s Board of Directors on November 13, 2026. Pursuant to the laws of the State of Nevada, the Company’s state of incorporation, the Company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company’s common stock will continue to trade on the NYSE American under the stock ticker "TOVX" but will trade under the new CUSIP number 87164U607.
